These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20829766)

  • 1. Rare victory in fight against melanoma.
    Ledford H
    Nature; 2010 Sep; 467(7312):140-1. PubMed ID: 20829766
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 3. Relief of inhibitory autophosphorylation activates RAF.
    Cancer Discov; 2013 Jul; 3(7):OF31. PubMed ID: 23847376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer research. Melanoma drug vindicates targeted approach.
    Garber K
    Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
    [No Abstract]   [Full Text] [Related]  

  • 5. Hope in translation.
    Nature; 2010 Sep; 467(7315):499. PubMed ID: 20881968
    [No Abstract]   [Full Text] [Related]  

  • 6. The pathway ahead in melanoma trials.
    Miller AJ; Markovic SN; Haluska P
    Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
    [No Abstract]   [Full Text] [Related]  

  • 7. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 8. Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.
    Tuma RS
    J Natl Cancer Inst; 2011 Feb; 103(3):170-1, 177. PubMed ID: 21242335
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF inhibitors: research accelerates in wake of positive findings.
    Brower V
    J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
    Long G
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectively targeting BRAF in melanoma: a formidable challenge.
    Fecher LA; Amaravadi R; Schuchter LM
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):410-1. PubMed ID: 18710372
    [No Abstract]   [Full Text] [Related]  

  • 12. In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
    Flaherty K
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):745-747. PubMed ID: 29040252
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in drug development. BRAF validation in melanoma.
    Flaherty K
    Clin Adv Hematol Oncol; 2010 Jan; 8(1):31-4. PubMed ID: 20351680
    [No Abstract]   [Full Text] [Related]  

  • 14. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
    Gallagher SJ; Thompson JF; Indsto J; Scurr LL; Lett M; Gao BF; Dunleavey R; Mann GJ; Kefford RF; Rizos H
    Neoplasia; 2008 Nov; 10(11):1231-9. PubMed ID: 18953432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
    Tucker H; Umeweni N; Robertson J; Adam J
    Lancet Oncol; 2014 Dec; 15(13):1425-1426. PubMed ID: 25499274
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug development: a chance of survival.
    Hoag H
    Nature; 2014 Nov; 515(7527):S118-20. PubMed ID: 25407709
    [No Abstract]   [Full Text] [Related]  

  • 18. New melanoma drug requires gene mutation test.
    Thompson CA
    Am J Health Syst Pharm; 2011 Oct; 68(19):1764. PubMed ID: 21930626
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncogenic RAF: a brief history of time.
    Solit D; Rosen N
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):760-2. PubMed ID: 20973931
    [No Abstract]   [Full Text] [Related]  

  • 20. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.